COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
Multiple-step methods versus single-step methods differentiated.
As the number of COVID-19 cases in the United States has increased, the availability of real COVID-19 positive specimens has also increased.
Segmented highlights from interim final rule CMS-5531-IFC, which was released with a 60-day comment period, effective May 8, 2020. Recent changes are intended to increase the COVID-19 response capabilities of providers and hospitals.
Major highlights of the FDA’s revised COVID-19 testing policy issued May 11, 2020.
Compare SARS-CoV-2 testing requirements for clinical laboratories and other facilities based on new 20-06-CLIA memo issued April 30, 2020.
Clinical laboratory directors may reduce their risk of fraud and waste by familiarizing themselves with these four areas of recent focus.
Multiple-step methods versus single-step methods differentiated.
As the number of COVID-19 cases in the United States has increased, the availability of real COVID-19 positive specimens has also increased.
Segmented highlights from interim final rule CMS-5531-IFC, which was released with a 60-day comment period, effective May 8, 2020. Recent changes are intended to increase the COVID-19 response capabilities of providers and hospitals.
Major highlights of the FDA’s revised COVID-19 testing policy issued May 11, 2020.
Compare SARS-CoV-2 testing requirements for clinical laboratories and other facilities based on new 20-06-CLIA memo issued April 30, 2020.
Clinical laboratory directors may reduce their risk of fraud and waste by familiarizing themselves with these four areas of recent focus.
